29th week of 2021 patent applcation highlights part 9 |
Patent application number | Title | Published |
20210220284 | Treatment Method and Product for Uterine Fibroids using Purified Collagenase | 2021-07-22 |
20210220285 | ACID RESISTANT CAPSULES | 2021-07-22 |
20210220286 | PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS SUNITINIB | 2021-07-22 |
20210220287 | PEPTIDE/PARTICLE DELIVERY SYSTEMS | 2021-07-22 |
20210220288 | NATURAL NANOPARTICLE-MEDICINE COMPOSITION FOR TREATING ALZHEIMER'S DISEASE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 2021-07-22 |
20210220289 | PARTICLES COMPRISING A THERAPEUTIC OR DIAGNOSTIC AGENT AND SUSPENSIONS AND METHODS OF USE THEREOF | 2021-07-22 |
20210220290 | COMPOSITIONS FOR MANAGING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2021-07-22 |
20210220291 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PULMONARY FIBROSIS | 2021-07-22 |
20210220292 | CANNABINOID AND ANESTHETIC COMPOSITIONS AND METHODS | 2021-07-22 |
20210220293 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 2021-07-22 |
20210220294 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 2021-07-22 |
20210220295 | TREATMENT OF CANCER BY GUANIDINIUM DERIVATIVES | 2021-07-22 |
20210220296 | COMBINATION FORMULATION CONTAINING COLCHICINE FOR TREATMENT OR ENHANCING THE THERAPY OF LIVER DISEASE | 2021-07-22 |
20210220297 | COMBINATIONS OF IRS/STAT3 DUAL MODULATORS AND ANTI-CANCER AGENTS FOR TREATING CANCER | 2021-07-22 |
20210220298 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING METABOLIC SYNDROME INDUCED BY ANTIPSYCHOTIC TREATMENT AND RELATED DISEASES AND CONDITIONS | 2021-07-22 |
20210220299 | A STABLE AQUEOUS HYDROXYCARBAMIDE SOLUTION | 2021-07-22 |
20210220300 | METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE | 2021-07-22 |
20210220301 | Pharmaceutical or Nutritional Combination Comprising Beta-Hydroxy-Betamethylbutyrate | 2021-07-22 |
20210220302 | BUTYRATE AND BETA-HYDROXYBUTYRATE COMPOSITIONS | 2021-07-22 |
20210220303 | FLURBIPROFEN AXETIL EMULSION FOR INJECTION AND PREPARATION METHOD THEREOF | 2021-07-22 |
20210220304 | METHODS OF TREATING UREA CYCLE DISORDERS AND MAPLE SYRUP URINE DISEASE | 2021-07-22 |
20210220305 | Treatment of intrahepatic cholestatic diseases | 2021-07-22 |
20210220306 | TREATMENT AND DIAGNOSIS OF MELANOMA | 2021-07-22 |
20210220307 | COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAIN | 2021-07-22 |
20210220308 | LEVODOPA FRACTIONATED DOSE COMPOSITION AND USE | 2021-07-22 |
20210220309 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF KIDNEY DAMAGE | 2021-07-22 |
20210220310 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER | 2021-07-22 |
20210220311 | APPLICATION OF VALINE IN PREPARING MEDICINE FOR TREATING OR PREVENTING AVIAN INFLUENZA VIRUS INFECTION | 2021-07-22 |
20210220312 | Compositions And Methods For Modulating Cancer | 2021-07-22 |
20210220313 | FORMULATION AND METHOD FOR THE PREVENTION AND/OR TREATMENT OF HANGOVER SYMPTOMS | 2021-07-22 |
20210220314 | AMINO ACID COMPOSITION FOR ENABLING FULFILMENT OF THE AMINO ACID REQUIREMENTS OF A MONOGASTRIC ANIMAL SUCH AS A HUMAN OR A PIG | 2021-07-22 |
20210220315 | NITRATED-FATTY ACIDS MODULATION OF TYPE II DIABETES | 2021-07-22 |
20210220316 | OPHTHALMIC COMPOSITIONS CONTAINING A NITRIC OXIDE RELEASING PROSTAMIDE | 2021-07-22 |
20210220317 | FUMARATE ESTER DOSAGE FORMS WITH ENHANCED GASTROINTESTINAL TOLERABILITY | 2021-07-22 |
20210220318 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | 2021-07-22 |
20210220319 | VETERINARY COMPOSITIONS AND THE USES THEREOF FOR CONTROLLING IRON DEFICIENCIES IN NON-HUMAN MAMMALS | 2021-07-22 |
20210220320 | ANALGESIC AGENT AND SEDATIVE AGENT | 2021-07-22 |
20210220321 | CRYSTAL FORMS OF TETRAHYDRO-N,N-DIMETHYL-2,2-DIPHENYL-3-FURANMETHANAMINE HYDROCHLORIDE, PROCESSES OF MAKING SUCH FORMS, AND THEIR PHARMACEUTICAL COMPOSITIONS | 2021-07-22 |
20210220322 | Disease Modifying Methods For Treating Neurodegenerative Diseases Using Nootropic Agents | 2021-07-22 |
20210220323 | COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE OR MINERAL | 2021-07-22 |
20210220324 | COMPOSITIONS COMPRISING COMBINATIONS OF PURIFIED CANNABINOIDS, WITH AT LEAST ONE FLAVONOID, TERPENE, OR MINERAL | 2021-07-22 |
20210220325 | TRANSDERMAL DELIVERY OF DRONABINOL | 2021-07-22 |
20210220326 | Compounds and Methods for Inhibiting CPY26 Enzymes | 2021-07-22 |
20210220327 | METHOD FOR TREATING NON-COMPACTION CARDIOMYOPATHY | 2021-07-22 |
20210220328 | PYRROLE DERIVATIVES AS ACC INHIBITORS | 2021-07-22 |
20210220329 | A METHOD OF TREATING TRIPLE-NEGATIVE BREAST CANCER | 2021-07-22 |
20210220330 | SYNERGIC PHARMACEUTICAL COMPOSITION OF THE ACTIVE ENANTIOMER (S)-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN | 2021-07-22 |
20210220331 | INHIBITORS OF IRES-MEDIATED PROTEIN SYNTHESIS | 2021-07-22 |
20210220332 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | 2021-07-22 |
20210220333 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR TREATING FILARIAL DISEASE | 2021-07-22 |
20210220334 | PHARMACEUTICAL COMBINATION, COMPOSITION AND COMPOUND PREPARATION CONTAINING GLUCOKINASE ACTIVATOR AND K-ATP CHANNEL BLOCKER, PREPARATION METHOD THEREFOR AND USE THEREOF | 2021-07-22 |
20210220335 | NITROIMIDAZOLE FORMULATIONS | 2021-07-22 |
20210220336 | TOPICAL DETOMIDINE FORMULATIONS | 2021-07-22 |
20210220337 | METHODS OF MODULATING ANTIGENICITY TO ENHANCE RECOGNITION BY T-CELLS | 2021-07-22 |
20210220338 | PHARMACEUTICAL COMPOSITION CONTAINING ANTIFUNGAL AGENT AS ACTIVE INGREDIENT | 2021-07-22 |
20210220339 | RAPAMYCIN ANALOGS AND USES THEREOF | 2021-07-22 |
20210220340 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISEASE | 2021-07-22 |
20210220341 | SECURININE AND NORSECURININE ANALOGUE COMPOUNDS FOR THE TREATMENT OF MYELOID DISORDERS | 2021-07-22 |
20210220343 | TREATMENT OF BURN PAIN BY TRPV1 MODULATORS | 2021-07-22 |
20210220344 | Methods Of Treating Fabry Patients Having Renal Impairment | 2021-07-22 |
20210220347 | METHODS OF SAFELY TRANSITIONING A SUBJECT TO BUPRENORPHINE | 2021-07-22 |
20210220348 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | 2021-07-22 |
20210220350 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PULMONARY HYPERTENSION COMPRISING MEBENDAZOLE AND/OR ITRACONAZOLE OR SALT THEREOF | 2021-07-22 |
20210220351 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | 2021-07-22 |
20210220352 | LEVOKETOCONAZOLE FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA AND PRIMARY ALDOSTERONISM | 2021-07-22 |
20210220353 | USE OF FAVIPIRAVIR IN TREATMENT OF CORONAVIRUS INFECTION | 2021-07-22 |
20210220354 | COMPOSITION FOR REDUCING NERVOUS SYSTEM INJURY AND METHOD OF MAKING AND USE THEREOF | 2021-07-22 |
20210220355 | ANTITUMOR AGENT FOR ACUTE MYELOID LEUKEMIA | 2021-07-22 |
20210220356 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | 2021-07-22 |
20210220357 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | 2021-07-22 |
20210220358 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH NERVE FIBER SENSITIZATION | 2021-07-22 |
20210220359 | Compositions and Methods for Treating Retinal Degradation | 2021-07-22 |
20210220360 | PALATABLE ANTIPARASITIC FORMULATIONS | 2021-07-22 |
20210220361 | SOLID DISPERSIONS OF A ERB2 (HER2) INHIBITOR | 2021-07-22 |
20210220362 | TLR7 AGONIST AND PHARMACEUTICAL COMBINATION THEREOF FOR TREATING LUNG CANCER | 2021-07-22 |
20210220363 | METHODS FOR INCREASING SEPIAPTERIN PLASMA EXPOSURE | 2021-07-22 |
20210220364 | COMBINATION THERAPY INVOLVING DIARYL MACROCYCLIC COMPOUNDS | 2021-07-22 |
20210220365 | TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS | 2021-07-22 |
20210220366 | CRYSTALLINE SALT COMPRISING 5-METHYL-(6S)-TETRAHYDROFOLIC ACID AND 4-(2-HYDROXYETHYL)-MORPHOLINE | 2021-07-22 |
20210220367 | INHALABLE FORMULATION OF A SOLUTION CONTAINING GLYCOPYRROLATE AND OLODATEROL HYDROCHLORIDE | 2021-07-22 |
20210220368 | COMPOSITIONS COMPRISING TIMOLOL AND THEIR USE IN THE TREATMENT OF ROSACEA BY TOPICAL ADMINISTRATION | 2021-07-22 |
20210220369 | HIGHLY POTENT TACC3 INHIBITOR AS A NOVEL ANTICANCER DRUG CANDIDATE | 2021-07-22 |
20210220370 | SELECTIVE HDAC8 INHIBITORS AND THEIR USES | 2021-07-22 |
20210220371 | METHOD FOR SMOKING CESSATION | 2021-07-22 |
20210220372 | COMPOSITIONS COMPRISING BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF | 2021-07-22 |
20210220373 | ORALLY DISINTEGRATING PHARMACUTICAL COMPOSITION COMPRISING NEFOPAM AND PROCESS FOR PREPARING THE SAME | 2021-07-22 |
20210220374 | METHODS OF TREATING TESTOSTERONE DEFICIENCY | 2021-07-22 |
20210220375 | STABLE READY TO USE CYCLOPHOSPHAMIDE LIQUID FORMULATIONS | 2021-07-22 |
20210220377 | USE OF SUBSTITUTED AMINOPROPIONATE COMPOUNDS IN TREATMENT OF SARS-COV-2 INFECTION | 2021-07-22 |
20210220378 | N-ACETYLNEURAMINIC ACID COMPOSITIONS AND METHODS OF USE | 2021-07-22 |
20210220379 | PERITONEAL SODIUM-GLUCOSE TRANSPORTER (SGLT) INHIBITORS FOR IMPROVEMENT OF PERITONEAL DIALYSIS | 2021-07-22 |
20210220380 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | 2021-07-22 |
20210220381 | A TOPOISOMERASE INHIBITOR FOR MIMICKING THE EFFECT OF IONIZING RADIATIONS ON T CELLS | 2021-07-22 |
20210220382 | ORAL COMPOSITION | 2021-07-22 |
20210220383 | LIPOPHOSPHONOXINS OF SECOND GENERATION, AND THEIR USE | 2021-07-22 |
20210220384 | ORAL ADMINISTRABLE PHARMACEUTICAL COMPOSITION | 2021-07-22 |
20210220385 | PET FOOD COMPOSITIONS | 2021-07-22 |
20210220386 | EXON SKIPPING OLIGOMERS AND OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY | 2021-07-22 |
20210220387 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF MICRORNA RELATED DISEASES | 2021-07-22 |
20210220388 | THERAPEUTIC HYDROGEL MATERIAL AND METHODS OF USING THE SAME | 2021-07-22 |